Patents by Inventor Christian Czech

Christian Czech has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DETERMINATION OF PARKINSON'S DISEASE
    Publication number: 20220018851
    Abstract: Methods and compositions for accurate identification of Parkinson's disease are disclosed. More particularly, the disclosure is directed to the determination of Parkinson's disease in ante-mortem tissue samples.
    Type: Application
    Filed: August 8, 2019
    Publication date: January 20, 2022
    Inventors: Christian Czech, Sebastian Dziadek, Lidija Pestic-Dragovich, Lei Tang, Thomas Kremer, Wagner Marcelo Zago, Tsu-Shuen Tsao, Adriana Racolta, Marta Canamero, Ronald Torres, Mirko Ritter
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 11124563
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: September 21, 2021
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Oligopeptide and methods for producing conjugates thereof
    Patent number: 10787505
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: September 29, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST PHOSPHORYLATED TAU PROTEINS AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20200165329
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Application
    Filed: December 2, 2019
    Publication date: May 28, 2020
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 10538582
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 21, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST PHOSPHORYLATED TAU PROTEINS AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20190077853
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Application
    Filed: September 25, 2018
    Publication date: March 14, 2019
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 10087245
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 2, 2018
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof
    Patent number: 9738712
    Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: August 22, 2017
    Assignees: F. HOFFMAN-LA ROCHE AG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CRNS), INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST PHOSPHORYLATED TAU PROTEINS AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20170058022
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Application
    Filed: January 28, 2015
    Publication date: March 2, 2017
    Applicant: F. HOFFMANN-LA ROCHE AG
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • OLIGOPEPTIDE AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20160355575
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Application
    Filed: November 13, 2014
    Publication date: December 8, 2016
    Applicants: F. Hoffmann-La Roche AG, Centre National de la Recherche Scientifique, Commissariat A L'Energie Atomique et Aux Energies Alternatives
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST AMYLOID BETA AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20160347831
    Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.
    Type: Application
    Filed: November 13, 2014
    Publication date: December 1, 2016
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • METHOD FOR THE IDENTIFICATION OF BETA-SHEET AGGREGATED PROTEIN LIGANDS
    Publication number: 20140363898
    Abstract: The present invention provides an assay for the identification of beta-sheet aggregated protein ligands using Thiazine Red R.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 11, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Edilio Borroni, Christian Czech, Arnulf Dorn, Luca Gobbi, Valerie Goetschy-Meyer, Fiona Grueninger, Doris Roth
  • Transgeneic animal expressing a multiple mutated form of presenilin 1
    Patent number: 8492610
    Abstract: The present invention relates to the field of transgenic animal models and more particularly the animal models of Alzheimer's disease. The invention relates to a transgenic animal expressing a multimutated form of presenilin 1 and allowing an apoptotic phenomenon to be detected in a renewable peripheral tissue.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: July 23, 2013
    Assignee: Aventis Pharma S.A.
    Inventors: Anne Eckert, Walter Muller, Christian Czech, Laurent Pradier, Gunter Tremp
  • Antibody that recognizes phosphorylated peptides
    Publication number: 20070280935
    Abstract: The present invention relates to an antibody which recognizes an epitope consisting of Ser-Ile-A1-A2-A3- A4-Ser(PO3H2)-Pro-Gln-Leu-Ala-Thr-Leu-Ala-A5 (SEQ ID NO: 9), and does not bind to an epitope consisting of Ser-Ile-A1-A2-A3- A4-Ser-Pro-Gln-Leu-Ala-Thr-Leu-Ala- A5 (SEQ ID NO: 8), wherein A1 is Asp or Asn, A2 is Met or Leu, A3 is Val or Leu, A4 is Asp or Glu and A5 is Asp or Glu, a hybridoma producing the antibody, a kit comprising the antibody, and a method for diagnosing a neurological disorder using the antibody.
    Type: Application
    Filed: June 29, 2007
    Publication date: December 6, 2007
    Inventors: Bernd Bohrmann, Christian Czech, Judith Gerlach-Weck, Fiona Grueninger
  • Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the &bgr;-amyloid peptide
    Patent number: 6653088
    Abstract: Provided herein are novel peptide and nucleotide sequences, their pharmaceutical use, as well as novel polypeptides capable of inhibiting at least partially the interaction between presenilin 1 or presenilin 2 and the &bgr;-amyloid peptide precursor or a &bgr;-amyloid peptide; also provided are in vitro tests and methods for detecting molecules and in particular, molecules capable of inhibiting said interaction.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: November 25, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Christian Czech, Luc Mercken, Laurent Pradier, Soline Reboul-Becquart
  • Display screen with transitional graphical user interface
    Patent number: D1007526
    Type: Grant
    Filed: May 3, 2023
    Date of Patent: December 12, 2023
    Assignee: F. Hoffman-La Roche AG
    Inventors: Christian Gossens, Michael Lindemann, Timothy Kilchenmann, Ignacio Fernandez Garcia, Joerg Sprengel, Christian Czech
  • Display screen with transitional graphical user interface
    Patent number: D1009050
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: December 26, 2023
    Assignee: F. Hoffman-La Roche AG
    Inventors: Christian Gossens, Michael Lindemann, Timothy Kilchenmann, Ignacio Fernandez Garcia, Joerg Sprengel, Christian Czech